Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IVF
INVO Fertility
$1.70
-2.0%
$0.00
$1.38
$17.04
$3.64M2.241.39 million shs22,872 shs
NanoVibronix, Inc. stock logo
NAOV
NanoVibronix
$1.20
+39.7%
$4.19
$0.67
$16.25
$1.00M2.031.10 million shs36.40 million shs
Tivic Health Systems, Inc. stock logo
TIVC
Tivic Health Systems
$4.26
+3.4%
$4.29
$2.43
$16.08
$3.74M2.03645,396 shs11,183 shs
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$0.16
$0.13
$0.06
$6.80
$3.41M0.46589,108 shs19,367 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IVF
INVO Fertility
+4.85%-11.73%+172,999,900.00%+172,999,900.00%+172,999,900.00%
NanoVibronix, Inc. stock logo
NAOV
NanoVibronix
-27.49%-27.49%-81.99%-77.77%-89.98%
Tivic Health Systems, Inc. stock logo
TIVC
Tivic Health Systems
0.00%-3.96%-36.32%-39.98%-40.85%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
+9.39%+1.76%+41.61%+33.11%-96.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
IVF
INVO Fertility
N/AN/AN/AN/AN/AN/AN/AN/A
NanoVibronix, Inc. stock logo
NAOV
NanoVibronix
0.3299 of 5 stars
0.02.00.00.02.60.00.6
Tivic Health Systems, Inc. stock logo
TIVC
Tivic Health Systems
0.3062 of 5 stars
0.04.00.00.01.60.00.0
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IVF
INVO Fertility
0.00
N/AN/AN/A
NanoVibronix, Inc. stock logo
NAOV
NanoVibronix
0.00
N/AN/AN/A
Tivic Health Systems, Inc. stock logo
TIVC
Tivic Health Systems
0.00
N/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
2.00
Hold$5.002,986.42% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IVF
INVO Fertility
$6.59M0.55N/AN/AN/A
NanoVibronix, Inc. stock logo
NAOV
NanoVibronix
$2.66M0.37N/AN/A$1.95 per share0.61
Tivic Health Systems, Inc. stock logo
TIVC
Tivic Health Systems
$516K7.25N/AN/A$2.44 per share1.75
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$7.68M0.44N/AN/A($6.91) per share-0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IVF
INVO Fertility
N/A-$34.06N/AN/AN/AN/AN/AN/A
NanoVibronix, Inc. stock logo
NAOV
NanoVibronix
-$3.71M-$13.53N/AN/A-93.80%-101.17%-53.03%8/12/2025 (Estimated)
Tivic Health Systems, Inc. stock logo
TIVC
Tivic Health Systems
-$8.24MN/A0.00N/A-670.95%-201.30%-154.54%N/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-$50.08MN/A0.00N/A-563.16%N/A-174.06%5/29/2025 (Estimated)

Latest NAOV, IVF, TIVC, and TTOO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
IVF
INVO Fertility
N/A-$12.53N/A-$12.53N/A$1.64 million
5/20/2025Q1 2025
NanoVibronix, Inc. stock logo
NAOV
NanoVibronix
N/A-$3.98N/A-$3.98N/A$1.02 million
5/15/2025Q1 2025
Tivic Health Systems, Inc. stock logo
TIVC
Tivic Health Systems
N/A-$2.52N/A-$2.52N/A$0.07 million
3/21/2025Q4 2024
Tivic Health Systems, Inc. stock logo
TIVC
Tivic Health Systems
-$85.00-$19.68+$65.32N/A$1.43 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
IVF
INVO Fertility
N/AN/AN/AN/AN/A
NanoVibronix, Inc. stock logo
NAOV
NanoVibronix
N/AN/AN/AN/AN/A
Tivic Health Systems, Inc. stock logo
TIVC
Tivic Health Systems
N/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IVF
INVO Fertility
N/AN/AN/A
NanoVibronix, Inc. stock logo
NAOV
NanoVibronix
N/A
1.74
0.84
Tivic Health Systems, Inc. stock logo
TIVC
Tivic Health Systems
N/A
5.65
4.34
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/A
0.40
0.24

Institutional Ownership

CompanyInstitutional Ownership
IVF
INVO Fertility
12.02%
NanoVibronix, Inc. stock logo
NAOV
NanoVibronix
16.39%
Tivic Health Systems, Inc. stock logo
TIVC
Tivic Health Systems
4.25%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
23.18%

Insider Ownership

CompanyInsider Ownership
IVF
INVO Fertility
1.79%
NanoVibronix, Inc. stock logo
NAOV
NanoVibronix
7.00%
Tivic Health Systems, Inc. stock logo
TIVC
Tivic Health Systems
0.31%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
IVF
INVO Fertility
102.15 millionN/AN/A
NanoVibronix, Inc. stock logo
NAOV
NanoVibronix
20826,0003.49 millionNot Optionable
Tivic Health Systems, Inc. stock logo
TIVC
Tivic Health Systems
10878,0009.44 millionNot Optionable
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
18021.04 million21.04 millionOptionable

Recent News About These Companies

T2 Biosystems initiates major layoffs, seeks asset sale
T2 Biosystems to be delisted from Nasdaq
T2 Biosystems reports preliminary Q4 revenue $2.3M
T2 Biosystems achieves milestone with 250,000th novel sepsis test shipped
T2 Biosystems extends multi-year supplier agreement with Vizient

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVO Fertility NASDAQ:IVF

$1.70 -0.04 (-2.02%)
As of 11:27 AM Eastern

NAYA Biosciences (NASDAQ: NAYA) is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility. Our hub & spoke model harnesses the shared resources of a parent company and agility of lean strategic franchises, enabling efficient acquisition, development, and partnering of assets as well as optimized return on investment by combining the upside of innovative clinical-stage therapeutics with scalable, profitable commercial revenues. NAYA’s expanding portfolio of assets currently includes NY-303, a GPC3 and NKp46 targeting bispecific antibody for the treatment of hepatocellular carcinoma (HCC) with a unique mode of action targeting non-responders to the current immunotherapy standard of care (approximately 70% of the current treatable market) cleared to enroll patients in a Phase I/II monotherapy trial in early 2025, NY-338, a CD38 and NKp46 targeting bispecific antibody for the treatment of multiple myeloma and autoimmune diseases with a differentiated safety and efficacy profile, and INVOcell®, an FDA-approved fertility device which has demonstrated comparable success rates to traditional In Vitro Fertilization (IVF).

NanoVibronix stock logo

NanoVibronix NASDAQ:NAOV

$1.20 +0.34 (+39.67%)
As of 12:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

Tivic Health Systems stock logo

Tivic Health Systems NASDAQ:TIVC

$4.26 +0.14 (+3.40%)
As of 12:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

T2 Biosystems stock logo

T2 Biosystems NASDAQ:TTOO

$0.16 0.00 (0.00%)
As of 11:40 AM Eastern

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.